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Abstract
Background: Decompressive laminotomy is the standard surgical procedure in the treatment of patients with canal 
stenosis related intermittent neurogenic claudication. New techniques, such as interspinous process implants, claim a 
shorter hospital stay, less post-operative pain and equal long-term functional outcome. A comparative (cost-) 
effectiveness study has not been performed yet. This protocol describes the design of a randomized controlled trial 
(RCT) on (cost-) effectiveness of the use of interspinous process implants versus conventional decompression surgery 
in patients with lumbar spinal stenosis.
Methods/Design: Patients (age 40-85) presenting with intermittent neurogenic claudication due to lumbar spinal 
stenosis lasting more than 3 months refractory to conservative treatment, are included. Randomization into 
interspinous implant surgery versus bony decompression surgery will take place in the operating room after induction 
of anesthesia. The primary outcome measure is the functional assessment of the patient measured by the Zurich 
Claudication Questionnaire (ZCQ), at 8 weeks and 1 year after surgery. Other outcome parameters include perceived 
recovery, leg and back pain, incidence of re-operations, complications, quality of life, medical consumption, 
absenteeism and costs. The study is a randomized multi-institutional trial, in which two surgical techniques are 
compared in a parallel group design. Patients and research nurses are kept blinded of the allocated treatment during 
the follow-up period of 1 year.
Discussion: Currently decompressive laminotomy is the golden standard in the surgical treatment of lumbar spinal 
stenosis. Whether surgery with interspinous implants is a reasonable alternative can be determined by this trial.
Trial register: Dutch Trial register number: NTR1307
Background
Intermittent Neurogenic Claudication (INC) is a complex
of symptoms first described by Van Gelderen in 1948 and
in 1950 by the Dutch neurosurgeon Verbiest, therefore
formerly known as the Verbiest syndrome [1-4]. The
characteristic symptom is described as leg pain (fre-
quently in both legs) which can be exacerbated with pro-
longed walking or lumbar extension. Others, like Evans,
describe a cramp, tightness or discomfort of the legs after
walking which diminish after a short period of sitting or
bending forward [1]. Apart from the leg pain, associated
low back pain may occur [5].
Since the description of neurogenic claudication by
Verbiest, explanation of the symptoms has been disputed.
Verbiest stated in 1954: "In the writer's humble opinion
the ligamentum flavum is most unlikely to contact any
spinal root unless this root is distorted from its regular
path"[4]. Evans showed in 1964 a cerebral spinal fluid
stop at the low lumbar levels narrowing of the canal by
degenerative facet arthrosis resulting in nerve root com-
p r e s s i o n .  I N C  i s  o f t e n  s e e n  i n  p a t i e n t s  w i t h  l u m b a r
degenerative spinal stenosis [4]. Due to this arthrosis of
the facet joints, lumbar nerve root compression will
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develop. Arnoldi described multiple types of lumbar spi-
nal stenosis. His article published in 1975 was actually a
summarization of a symposium on this subject [4,6].
Presently, his classification is still widely used. Like in any
acquired disease, INC is usually seen in the elderly [1].
The best treatment of NIC due to lumbal stenosis
remains controversial [5,7]. Nonoperative therapy like
epidural steroid injections, nonsteroidal anti-inflamma-
tory medication, analgesics, physical therapy, and spinal
manipulation, is frequently performed [8]. A 2005
Cochrane review found that the paucity and heterogene-
ity of evidence limited conclusions regarding surgical effi-
cacy for spinal stenosis [7,9-12]. Indeed, Weinstein et al
published in his article the results of a randomized cohort
study with relatively poor results in the non-operative
group [13-15]. Despite the high level of crossovers in
their study, the treatment effect was favoring surgery on
the SF-36 scale for bodily pain. Also Malmivaara et al
showed a better recovery after surgery versus conserva-
tive treatment with a difference of improvement of 11.3
on the ODI disability scale [16]. Furthermore Turner et al
published in their attempted meta-analysis a success rate
(good to fair outcome) of 64% after surgical bony decom-
pression in patients with INC [17].
Thomé et al prospectively compared the most typically
used techniques: laminectomy, unilateral laminotomy
and bilateral laminotomy [18]. In the series of Thomé et
al, bilateral laminotomy achieved an 80% success rate. It
was slightly better compared to laminectomy, which had
70% success rate [18]. Many authors claim that bony
decompressive surgery might facilitate spinal fusion in
the future [19,20]. Furthermore, local trauma in these
surgical strategies should not be underestimated [21].
The above described operations are usually performed
under general or local anaesthesia and 2 to 7 days hospi-
talization may be required, followed by an 8-weeks recov-
ery period. Furthermore, the clinical outcome seems
disappointing, since 35% of the patients documented bad
outcome [13-17].
Minimally invasive surgery has gained popularity in
recent years, resulting in the development of interspinous
implants in the 1980s [22]. One of these models, the Wal-
lis device, was made with a band around the spinous pro-
cesses. Later in 2003 X-stop, in 2005 Diam, in 2006
Coflex, and afterwards various other kinds of forms were
developed to stabilize or distract the interspinous dis-
tance [23-33]. These implants are all placed between
spinous processes, which will lead to distraction of the
interspace with consequent indirect decompression of
the nerve roots. Presently, most publications refer to X-
stop implants [8,23-26,29-31,34-36]. It is claimed that this
indirect decompression will reduce the pressure on the
nerves leading to a return to a neutral or slightly tight-
ened position of the vertebral column. Nevertheless, this
is a far smaller operation and gives perhaps less destruc-
tion to the bony elements of the vertebral column. There-
fore, IPD is believed to have better short-term recovery
and similar long-term (cost-) effectiveness [8,34,36,37].
Outcomes were reported to be quite favorable in selected
series of poor methodological quality. The first random-
ized multicentre study on interspinous devices compared
X-stop with non-surgical treatment [36]. After 2 years,
the IPD group shows both clinically and statistically sig-
nificant improved results in comparison with the conser-
vative treated group [8,36]. However, this trial only
compared IPD with conservative treatment. Good evi-
dence on IPD versus other surgical treatment is not yet
available. Verhoof et al reported in 2008 a high failure rate
in IPD (X-stop), with an average slip on the radiographs
of 19.6%, and a high surgical re-intervention rate (seven
out of the 12) [35]. Strömqvist reported 13 re-operations
in a group of 50 patients [38]. Park et al published one of
the few studies with the Coflex implant [39]. However
they only placed a Coflex implant after bony decompres-
sion [40]. Furthermore long term results, despite from
the small retrospective series (twenty patients) of Kon-
drashov et al, are not yet available [34].
The golden standard in surgical treatment for lumbar
spinal stenosis is bony decompression to which all new
techniques should be compared. The purpose of our
study is to asses whether IPD-surgery is more (cost) effec-
tive compared with surgical decompression in patients
with INC due to lumbar stenosis. It is hypothesized that
IPD gives particularly a favorable short term effect,
necessitating a short term evaluation.
Methods/design
An observer and patient blinded randomized (cost-)effec-
tiveness trial in the treatment of lumbar spinal stenosis is
presented. In this trial two surgical techniques are com-
pared in a parallel group design. The primary outcome
measurement is the Zurich Claudication Questionnaire.
The follow-up period will last 1 year. In order to collect
enough patients, a multi-center design is necessary. The
study protocol was approved in all participating hospitals
(see table 1: list of hospitals).
Our primary question is whether IPD-surgery is more
(cost-)effective compared with surgical decompression
after 8 weeks in people with intermittent neurogenic
claudication due to lumbar stenosis. The main advantage
of IPD might be a faster recovery after surgery, but after
long term follow-up it is unknown if this treatment effect
will remain. Therefore, in addition, long-term follow-up
(one year) will be compared with short-term follow-up.
Patients
All patients between 40 and 85 years with at least three
months of INC due to spinal canal stenosis are eligible forMoojen et al. BMC Musculoskeletal Disorders 2010, 11:100
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this study. Imaging studies (MRI) must confirm a nar-
rowed lumbar spinal canal, nerve root canal or interver-
tebral foramen at one or two levels. Patients have
received at least three months of conservative therapy.
Lumbar discectomie is not possible during IPD surgery.
Therefore, patients should be excluded when a surgical
relevant herniated disc is present. Additional inclusion
and exclusion criteria are listed in table 2 (inclusion and
exclusion criteria).
Patients are referred by a neurologist with MRI and
conventional imaging of the lumbar spine. During the
first visit to the neurosurgical outpatient clinic, the
patient's history and a standard neurological examination
will be documented. Conform our selection criteria, the
neurosurgeon decides whether a patient is eligible for the
Felix (Foraminal Enlargement Lumbar Interspinous dis-
traXion) trial and informs the patient about both surgical
techniques. The study, with both treatment options, will
be explained to patients and, in case of a positive reac-
tion, appointments are made with research nurses.
Because the patient needs some time to consider partici-
pation, the first visit to the research nurse is planned after
at least 2 days. After informed consent, the question-
naires, outcome measures and baseline variables are
recorded.
Ethical considerations
In concordance to the decloration of Helsinki, the study
has been reviewed by an independent ethical committee
and approved as being ethically constituted. The design
of this study is approved by the Leiden Ethical Medical
Committee. Every participating center independently
needs an approval before they may include patients for
Table 2: inclusion and exclusion criteria
Exclusion/Inclusion Reason
Patient will be excluded signed informed consent
40 to 85 years
has INC, as noted by leg/buttock/groin pain with or without back pain
at least three months conservative treatment
has a regular indication for surgical intervention INC
has a narrowed lumbar spinal canal, nerve root canal or intervertebral foramen at one or two levels 
confirmed by MRI
is physically and mentally willing and able to comply with, or has caregiver why is willing and able to 
comply with, the post-operative evaluations
Patient will be included has a cauda equina syndrome
has a herniated disc at the same level, necessitating lumbar discectomy
has Paget's disease, severe osteoporosis or metastasis to the vertebrae
has significant scoliosis (Cobb angle >25 degrees)
has had previous surgery of the same lumbar level
has degenerative spondylolisthesis > grade 1 (scale 1 to 4) at the affected level
has significant instability of the lumbar spine
has severe co morbid conditions
has a fused segment at the indicated level
Table 1: list of hospitals participating in the Felix Trial
NH o s p i t a l
1 Leiden University Medical Centre
2 Medical Centre Spaarne, Hoofddorp
3 Medical Centre Rijnland, Leiderdorp
4 Medical Centre Diaconessenhuis, Leiden
5 Medical Centre Haaglanden, The Hague
6 Medical Centre Bronovo, The Hague
7 Medical Centre Groene Hart, Gouda
8 Medical Centre Reinier de Graaf, Delft
9 Medical Centre Vlietland, Schiedam
10 Medical Centre Canisius Wilhelmina, Nijmegen
11 Medical Centre Haga, The Hague
12 Medical Centre Isala, Zwolle
13 Medical Centre Alkmaar
14 Medical Centre Tergooier, Hilversum
15 University Medical Centre Leiden
N, number of participating hospital in order of participating in 
this Felix TrialMoojen et al. BMC Musculoskeletal Disorders 2010, 11:100
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this trial. Freely given informed consent will be obtained
from a patient before inclusion in this study. This means
that a patient has the right to know that he is being asked
to take part, and that he does not have to do so unless he
chooses. The patient will also be informed that there will
be no financial rewards if he or she agrees to participate.
Randomization procedure
Patients will be randomly allocated to either IPD or con-
ventional decompression. Randomization will take place
in the operating room within 4 weeks after inclusion by
the research nurse. A randomized block design, stratified
by hospital and research nurse, is used to ensure equal
distribution of both treatments while ensuring by impos-
ing a variable, random block size that the next treatment
is not predictable for the surgeon. The randomization
was prepared by the study statistician and the principle
data manager at the department of Biostatistics. They
were not involved in the selection and allocation of
patients and prepared coded, sealed envelopes containing
the treatment allocation. In the operating room, after
induction of anesthesia, the surgeon will open the enve-
lope and the allocated treatment will be performed.
Patients, nursery department and research nurses are
kept blinded for the allocated treatment during the fol-
low-up period of 1 year. The operation report will be kept
separately and will only be available in case of complica-
tions or reoperations.
Interventions
After the induced general anesthesia, randomization in
group (A) IPD and (B) surgical decompression will be
performed. The patient is positioned in knee-elbow posi-
tion or prone, dependent by the preference of the sur-
geon. The affected spinal level is verified fluoroscopically.
The participating surgeons have experience in both tech-
niques and performed at least five implant operations and
15 bony decompression operations.
A) IPD
A median lumbar incision is made over the spinous pro-
cesses, the laminae of the affected level(s) are exposed
subperiosteally, and the supraspinous ligament will be
incised. The interspinous ligament of the affected level is
removed. No decompression will be performed and the
ligamentum flavum will remain intact. A Coflex™ device
is placed in the created space between the spinous pro-
cess with insertion of instrumentation. The wound will be
closed in layers with a suction drain. The titanium
Coflex™ implant that fits between the spinous processes
of the lumbar spine is comprised of two components: a
wing assembly and a spacer assembly. The Coflex™ is
available in 5 sizes: 8 mm, 10 mm, 12 mm, 14 mm and 16
mm. The size refers to the minor diameter of the oval
spacer assembly of the Coflex™. Patients will be operated
with loupe magnification or microscope depending sur-
geon's preference. When an IPD fails, a standard lamino-
tomy will be performed.
B) Surgical decompression
Similarly as in group A, a median lumbar incision will be
made and the paravertebral muscles will be dissected
subperiosteally and retracted bilaterally. Decompression
will be applied via partial resection of the affected lami-
nae and no complete laminectomy will be performed.
The lateral recess will be opened bilaterally and medial
facetectomy will be performed in order to maintain sta-
bility of the segments. The wound will be closed in layers
with a suction drain. Like in the IPD group, patients will
be operated with loupe magnification or microscope
depending on the surgeon's preference.
The patient will be allowed to leave the bed and walk
without aid on the day of surgery. If the patient regains
his/her physical function, the patient will be discharged.
In both studies, patients and their guided physiothera-
pists are stimulated to resume home activities and work
as soon as possible. The latter are blinded for the allo-
cated treatment arm as well.
Baseline data
The baseline questionnaire assesses demographics, hob-
bies, sports, work status, smoking status, low back pain
history, family history of INC, co-morbidity, weight and
length. The patient's satisfaction at work will be regis-
tered. The patient's and the surgeon's treatment prefer-
ence for IPD or decompression surgery will be assessed
on a 5-point scale ranging from "strong preference for
IPD" to "strong preference for decompression surgery".
Outcome assessment
The validated outcome parameters described below will
be used in this study and assessed by means of question-
naires. Follow-up examinations by the research nurse will
take place at 2, 4, 8 weeks, 3, 6, 12, 24 and 60 months after
randomization (see table 3: flowchart). Patients will be
neurologically examined (at 8 weeks, 6, 12, 24 and 60
months) and the main questionnaires will be filled out at
home with a request to complete and return them. The
outpatient control by the neurosurgeon will be at 8 weeks
and more often if necessary (see table 3: flowchart).
Primary outcome measurement
The disorder-specific functional score will be the primary
outcome measure and can be obtained by completing the
ZCQ, also known as the Brigham Spinal Stenosis Ques-
tionnaire and Swiss Spinal Stenosis Questionnaire [41-
43]. The ZCQ scale consists of 3 subscales: symptom
severity, physical function and patient satisfaction.
Domain scores ranges from 1 to 5, 1 to 4, and 1 to 4
respectively. Like in the study of Tuli in 2006, we chose
threshold scores for each scale based on prior work [41-Moojen et al. BMC Musculoskeletal Disorders 2010, 11:100
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Table 3: Flowchart
Obtained patients' information V1 V2 V3 V4 V5 V6a V7 V8 V9 V10
In-patient x
O u t - p a t i e n t x xxxxxx
Demography & diagnosis x
Basic physical examination x
Neurological examination x x x x x x
Provide study information x
Obtain informed consent x
X-ray x x
Randomisation x
Z C Q x xxxxxxxx
M R D Q x x xxxxxx
S h u t t l e  W a l k i n g  T e s t x xxxxxx
S F - 3 6 x xxxxxxx
M c G i l l  P a i n  Q u e s t i o n n a i r e x xxxxxx
V A S  f o r  l e g s  a n d  b a c k x xxxxxxxx
P e r c e i v e d  R e c o v e r y xxxxxx
Patient Global Impression of 
change
xxxxxx
E u r o Q o l  &  V A S  Q u a l i t y  o f  L i f e x xxxxxxxx
Patient diary x x x x x x
Review MRI x
Complications x x x x x x x x
R e - o p e r a t i o n xxxxxx
A, questionnaires will be sent per mail with request to complete and return them; V1, Visit 1 - Intake; V2; Visit 2 - surgery; V3, Visit 3 - Follow-up 2 
weeks; V4, Visit 4 - Follow-up 4 weeks, V5, Visit 5 - Follow-up 8 weeks; V6, Visit 6 - Follow-up 3 months; V7, Visit 7: Follow-up 6 months; V8, Visit 8 
- Follow-up 12 months; V9, Visit 9 - Follow-up 24 months; V10, Visit 10 - Follow-up 60 months
44]. In the symptom severity scale and in the physical
function scale the minimal clinically important difference
(MCID) is 0.5. A mean patient satisfaction score of less
than 2.5 has been shown previously to represent a satis-
fied patient [42,43]. Despite from the subscale analysis we
dichotomize "succes" and "failure". When the MCID
threshold was achieved in at least two domains, it was
described as an overall succes [44].
Secondary outcome measurements
1) Modified Roland Disability Questionnaire for 
Sciatica (MRDQ) The 23-points MRDQ is the most
widely used patient -assessed measure of health for low
back pain and leg pain [45-52]. This questionnaire consist
of 23 questions with higher scores indicating increased
disability [53]. Patrick et al compared MRDQ to patients
satisfactory after from a change of 5 or more, patients feel
themselves better. From a change of 12.4 all symptoms
are completely gone. Others used a change of 4 or more
[7]. The MRDQ will be dichotomized in "good result"
(change of 4 or more) and "poor result" (change of 4 or
less) [49-51].
2) Shuttle walking test (SWT) In this test a distance of
ten meters has to be walked by the patients in a certain
amount of time. This interval will be shortened until the
patient does not finish the ten meters in the prescribed
time. The SWT needs to change by 76 meters to ensure
that walking distance is changed, but large changes can
occur after surgery, and the SWT may thus provide a use-
ful measure on an individual basis [54].
3) SF-36 The questionnaire consists of 36 items on physi-
cal and social status of the patient subdivided in 8
domains: physical function, physical restrictions, emo-
tional restrictions, social functioning, somatic pain, gen-
eral mental health, vitality, and general health perception.
The questions are scored on a scale of 0, "worst health", to
100, "ideal health" [55,56].
4) McGill pain questionnaire This score distinguishes
three dimensions of pain: sensoric, affective and evalua-
tive dimension [57,58].Moojen et al. BMC Musculoskeletal Disorders 2010, 11:100
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5) Visual Analogue Scale (VAS) score of back pain and 
leg pain This parameter will measure the experienced
back and leg pain intensity in the week before visiting the
research nurse. Pain will be assessed on a horizontal 100
millimeters scale varying from 0 millimeter, "no pain", to
100 millimeters, "the worst pain imaginable" [59].
6) Likert scale This 7-point perceived recovery scale var-
ies from "completely recovered" to "worse than ever". Like
the patient global impression of change, the scale will be
completed by the patient and research nurse. For analysis
purposes this test will be dichotomized in "recovered"
and "not recovered" [60].
7) Hospital Anxiety Depression Scale (HADS) This
scale consists of a 7-item depression scale and a 7-anxiety
scale. The score range from 0-21 with a high score being
indicative for depression/anxiety.
Costs
To estimate utilities the EuroQol is used [61-64]. The
EuroQol consists of 5 dimensions: mobility, self-care,
daily activities, pain/discomfort, and anxiety/depression.
Together with the remaining life expectation, they form
QALY's. The QALY is a measure for the number of years
someone still may expect, corrected for their quality. The
EuroQol will be repeated once every two weeks during
the first 8 weeks after surgery. These frequent EuroQol
measurements during the first 8 weeks have been chosen
in order to record the changes of quality of life. After this
first period EuroQol will be recorded on regular basis
during the patient's visit to the research nurse (see table
3: flowchart). The patients are also instructed to record a
diary in which, for example, work activities will be
enlisted. Furthermore direct medical costs will be esti-
mated on basis of the cost centre method.
Complications and re-operation incidence
The research nurse and the neurosurgeon will record
complications accurately. This may include infections,
post-surgical haematoma, cerebrospinal fluid leakage, an
increase in neurological deficit due to surgery, venous
thrombosis and other side effects.
Sample Size
The sample size calculation is based on the hypothesis
that the short-term results obtained after IPD are equal to
the results obtained after surgical decompression. The
ZCQ at eight weeks will be used as a primary result mea-
sure both to answer the first research question and to cal-
culate the sample size. The sample size of the trial is
based on a superiority design and calculated under the
alternative null-hypothesis to reach sufficient power to
enable a distinction between the two arms in terms of
success according to ZCQ if (according to the literature)
results obtained after surgical decompression will be 64%
and the results obtained after IPD will be at least 84%
( 2 0 %  d i f f e r e n c e  i n  f a v o r  o f  I P D ) .  A  s a m p l e  s i z e  o f  9 8
patients per group ensures 90% power to confirm the null
hypothesis when IPD is more than 20% superior to
decompression, using a likelihood ratio test in a logistic
regression framework (see figure 1: sample size).
Accounting for about 10% loss to follow-up, this trial will
enroll 216 patients with INC (108 patients in both
groups). A sample size of 80 patients per group (including
10% loss to follow-up) will ensure a power of 80%. The
feasibility of reaching 216 patients available for analysis
will be checked after reaching 160 evaluable patients
without deblinding or even analyzing the data as a group
comparison. This constitutes a methodological valid
approach since no multiple testing is involved and stop-
ping further accrual is not based on an intermediate
effect estimate. Since the power is based on a dichotomi-
zation of the underlying ZCQ scale, an alternative pri-
mary analysis of the ZCQ itself will also have sufficient
power. The latter analysis will also take the repeated mea-
surements structure into account.
Statistical analysis
Baseline comparability will be assessed by descriptive sta-
tistics to determine whether randomization was success-
ful. Differences in outcome between both groups,
together with 95% confidence intervals, will be calcu-
lated. Besides a difference in recovery between the two
groups at two specified time points (eight weeks and one
year), analysis of a difference in time to recovery will be
carried out as well, using a survival analysis framework
(COX hazards). All data are analyzed according to the
"intention-to-treat-principle". Furthermore a repeated
measurements analysis of variance will be performed on
the underlying continuous scales. In all analyses the first
assessment of treatment effect will be the estimate of the
main effect within the appropriate model, adjusted for
Figure 1 Sample Size. N1: number of patients needed in the IPD 
group, P1: the chosen succes rate of the IPD group; P2: the succes rate 
of the decompression group (0.64); N2: number of patients needed in 
the decompression group (equal to N1); A: the alfa is two sided 0.05.Moojen et al. BMC Musculoskeletal Disorders 2010, 11:100
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the stratification factors and main covariates. Secondly,
an interaction term evaluating a possible effect modifica-
tion of the treatment effect by the major covariates (see
table 4: covariates for sub analysis) is pre-specified as
being part of proper statistical modeling of the primary
treatment effect. In the presence of severe interaction, the
treatment effect will be presented as a function of the
effect modifiers. In addition, an explorative subgroup
analysis is conducted to investigate whether treatment
effect varies over specific subgroups of patients (table 5:
subgroups). Data will be stored via the internet-based
secure data management system ProMISe of the depart-
ment of Medical Statistics and Bioinformatics. The analy-
ses will be carried out using appropriate statistical
software (e.g. SPSS, version 17).
Discussion
In this article a design of a RCT is presented which evalu-
ates the (cost-) effectiveness of IPD versus decompression
surgery in the treatment of intermittent neurogenic clau-
dication. This is the first randomized prospective trial
comparing these two surgical techniques. Like the Sciat-
ica-MED trial, the research nurse and the patient are
blinded for the allocated treatment [7]. The objective of
this trial is to determine whether the IPD is more (cost-)
effective after eight weeks compared to the conventional
decompression surgery.
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